Latest news on Alzheimer's
Check out the latest news about Alzheimer's disease research that we carry out at the Barcelonaβeta Brain Research Center (BBRC). Discover the advances in Alzheimer's prevention in which our scientists participate, as well as the news of the Alfa Study, dedicated to the early detection and prevention of the disease.
A new research drug against Alzheimer's confirms its positive results during CTAD
The results, published in The New England Journal of Medicine, confirm that lecanemab slows cognitive decline by 27% in patients in the early stages of Alzheimer's disease.
Dr. Juan Domingo Gispert presents the results of AMYPAD at an FDA seminar
The BBRC researcher and group leader gave a presentation on sources of variability in quantitative amyloid PET metrics
The validity of nine biomarkers for diagnosing Alzheimer's disease in daily clinical practice has been determined
A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre and the University of Gothenburg has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres.
New data indicate an association between poor sleep quality and an increased risk of developing Alzheimer's
The research, within the European project EPAD, is headed by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, together with the University of Bristol.
Raffaele Cacciaglia receives the Ramón y Cajal 2021 grant
The award is a recognition of the trajectory of the researcher, recipient in addition to a Knowledge Generation Project 2021
Relationship between symptoms of anxiety and depression during confinement and subjective cognitive decline found
In the research, led by the BBRC, 250 people without cognitive alterations from the ALFA Study, promoted by the ”la Caixa” Foundation, have participated.
The AMYPAD project is successfully completed
The consortium has officially ended its formal operation after six years of joint efforts and collaboration.
Positive results of a new drug against Alzheimer's
As indicated by Biogen y Eisai, the results show a 27% slowing of cognitive impairment in patients in the early stages of Alzheimer's disease.
Demonstrated a greater consumption of cerebral glucose in the early stages of Alzheimer's associated with the activation of astrocytes
In the research, led by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, 314 people without cognitive alterations from the Alfa Study, which has the support of the ”la Caixa” Foundation, have participated - DESTACAT
